Myasthenia gravis, Systemic lupus erythematosus, CIDP etc
Conditions
Interventions
Medication (new replacement fluid)
Sponsors
Adachi Masataka
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The study is open to those who meet all of the following criteria: - Patients (regardless of gender) who require inpatient treatment and simple plasma exchange therapy - Patients aged 18 years or older who have provided written consent from themselves or their legal representative
Exclusion criteria
Exclusion criteria: Those who meet the following criteria will be excluded: - Those deemed inappropriate as subjects of this study by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Incidence rate of adverse events and side effects occurring during plasma exchange treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| (1)Safety Evaluation - Changes in vital signs measured before, during, and after plasma exchange - Changes in the following laboratory values measured before and after plasma exchange. Blood gas analysis also performed during plasma exchange Albumin level, Fibrinogen level, Electrolytes( Na, K, Ca, Mg, Cl, P) Blood gases(Bicarbonate ion ( HCO3-), ionized calcium concentration, pH (2)Efficacy Evaluation - Changes in the following laboratory values measured before and after plasma exchange Antibody levels( IgG,IgM,IgA) | — |
Contacts
Public ContactMasataka Adachi
Kumamoto University Hospital
Outcome results
None listed